# A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

Source: https://onco.cc/trials/nct07553988/  
OnCo record `nct07553988` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abiraterone acetate, Prednisone in prostate cancer, run by R-Pharm International, LLC, active and no longer recruiting.

## Summary

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer is a phase 2 interventional study registered as NCT07553988 by R-Pharm International, LLC, with 120 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-05-14. Interventions recorded: RS-113, 160 mg, RS-113, 240 mg, RS-113, 320 mg, Abiraterone, Prednisolone. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07553988
- Phase: 2
- Setting: A Phase II, Open-label, Randomized, Comparative Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
- Sponsor: R-Pharm International, LLC
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07553988: https://clinicaltrials.gov/study/NCT07553988

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [R-Pharm](https://onco.cc/companies/r-pharm/)

---
JSON: https://onco.cc/api/v1/entities/nct07553988.json